By On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer (MIBC).
Top News
- Pain and Arthritis Products Containing Hidden Ingredients
- Painflex Forte may be harmful due to hidden drug ingredients
- Optikem International Inc. – 680264 – 06/20/2024
- Laboratorio Magnachem International – 673796 – 06/18/2024
- reBom Co., Ltd. – 682811 – 06/26/2024
- Max Chemical Inc. – 682037 – 06/20/2024
- 6 Things to Do in Ennis, Texas—From Bluebonnet Trails to a Railroad Museum
- ATM Glitch is Causing Chase to Sue Over 1,000 People—Were You Part of It?
- She Rescued a Dog on a Mountain—And He Rescued Her Family, Too
- April 21 to April 27 Horoscope Forecast: Your Zodiac Sign’s Week
- More Money Found: 11 Refunds and Credits You Can Get on Common Expenses
- 8-Year-Old Makes Easter Baskets for Hundreds of Kids in Need!
- China jumpstarts humanoid robot production with EV sector support
- Taiwan taps private sector for unmanned naval defense push
- CATL to mass-produce first sodium-ion battery by year-end
- Foxconn unveils AI-integrated EV, marking major push into global auto market
- Tesla’s 2025 slowdown reveals limits of the Musk playbook
- Taiwan rides AI wave as US tech orders surge
